Abstract Number: 2756 • 2014 ACR/ARHP Annual Meeting
Treatment of Mucocutaneous Manifestations in Behçet’s Disease with Anakinra: A Pilot Open-Label Study
Background/Purpose: IL-1 blocking therapy shows promise in the treatment of Behçet’s eye disease, but its effect on mucocutaneous manifestations is unknown. Methods: 6 patients with…Abstract Number: 2757 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of ANTI-TNF ALPHA in BEHÇET Disease: A International Multicenter Registry of 122 Patients
Background/Purpose Behçet’s disease (BD) is a systemic large vessel vasculitis with recurrent genital and oral ulceration, uveitis, cardiovascular, joints, neurological or gut symptoms. Treatment of…Abstract Number: 2758 • 2014 ACR/ARHP Annual Meeting
Predictive Factors for the Response to Infliximab Therapy in Patients with Behçet’s Disease
Background/Purpose: To identify the clinical factors predicting a good clinical response to Infliximab (IFX) therapy after 12 months in patients with Behçet’s disease (BD) refractory…Abstract Number: 2759 • 2014 ACR/ARHP Annual Meeting
Anti-TNF Treatment for Refractory Vascular Involvement of Behçet’s Syndrome
Background/Purpose: The optimal management of major vascular involvement in patients with Behçet’s syndrome (BS) is still a challenge. Methods: We reviewed the charts of 16…Abstract Number: 2760 • 2014 ACR/ARHP Annual Meeting
Interferon Alfa-Associated Depression in Patients with Behçet’s Syndrome
Background/Purpose: Interferon (IFN) is an effective immune-modulatory agent in the medical management of eye disease of Behçet’s syndrome (BS). The agent is frequently associated with…Abstract Number: 2761 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Parenchymal Neurological Involvement in Behcet’s Syndrome Patients with Panuveitis
Background/Purpose Behcet’s Syndrome (BS) is a systemic vasculitis which may involve multiple organ systems simultaneously. Most frequently, clinical findings in BS fit into well recognized…Abstract Number: 2762 • 2014 ACR/ARHP Annual Meeting
Atrophy of Hippocampal Region in Chronic Progressive Neuro-Behçet’s Disease
Background/Purpose: Central nervous system involvement in Behçet's disease, usually called neuro-Behçet's disease (NB), can be classified into acute NB (ANB) and chronic progressive NB (CPNB)…Abstract Number: 2763 • 2014 ACR/ARHP Annual Meeting
Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet’s Disease
Background/Purpose: Chronic progressive neurological manifestations in Behcet's disease (BD) is characterized by progressive deterioration leading to disability either with or without a history of previous…Abstract Number: 2764 • 2014 ACR/ARHP Annual Meeting
S100B Astrocyte Protein May Serve As a Prognostic Factor in Reversible Cerebral Vasoconstrictive Syndromes
Background/Purpose: Reversible Cerebral Vasoconstriction Syndromes (RCVS) are a group of disorders characterized by acute onset of recurrent thunderclap headaches with or without neurologic deficits. Radiologically,…Abstract Number: 2765 • 2014 ACR/ARHP Annual Meeting
Putative Blood Biomarkers of Reversible Cerebral Vasoconstriction Syndrome
Putative blood biomarkers of Reversible Cerebral Vasoconstriction Syndrome Background/Purpose The pathophysiology and molecular mechanisms of Reversible Cerebral Vasoconstriction Syndrome (RCVS) are unknown. Objective of the…Abstract Number: 2766 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil in the Treatment of Primary Central Nervous System Vasculitis
Background/Purpose . The optimal management of primary central nervous system vasculitis (PCNSV) remains unclear. Cyclophosphamyde (CYC) in combination with glucocorticoids (GCs) or GCs alone are…Abstract Number: 2767 • 2014 ACR/ARHP Annual Meeting
Core Outcome Domains and Potential Measurement Instruments in polymyalgia Rheumatica (PMR) Using Omeract Filter 2.0
Background/Purpose The OMERACT PMR specialist interest group was established to develop a core outcome measurement set for PMR using the methods of OMERACT filter 2.0.…Abstract Number: 2768 • 2014 ACR/ARHP Annual Meeting
Patient Reported Outcomes and Acute Phase Reactants in Polymyalgia Rheumatica in Patients Treated with Prednisone Versus Modified-Release Prednisone
Background/Purpose Polymyalgia rheumatica (PMR) is a chronic inflammatory disorder of the elderly, characterised by morning stiffness, pain and aching in the hip and shoulder girdles…Abstract Number: 2769 • 2014 ACR/ARHP Annual Meeting
Validation of New 2012 EULAR/ACR Classification Criteria for Polymyalgia Rheumatica: Comparison with the Previous Criteria in a Prospective Multi-Center Study
Background/Purpose: To evaluate the diagnostic and discriminative ability of the new 2012 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) polymyalgia rheumatica (PMR) classification…Abstract Number: 2770 • 2014 ACR/ARHP Annual Meeting
Polymyalgia Rheumatica Relapse and “Silence” Large Vessel Vasculitis. Is There Any Association?
Background/Purpose Large Vessel Vasculitis (LVV) can present with heterogeneous clinical manifestations, which range from general symptoms (fever, loss of weight) to the classic symptoms of …
ACR Meeting Abstracts